Table 1.
Patient and Disease Characteristics
| Characteristic | Foscarnet | No Foscarnet |
P Value |
|---|---|---|---|
| Number of patients | 25 | 61 | |
| Male sex, n (%) | 14 (56) | 42 (69) | .26 |
| Age at transplantation, yr, median (range), (IQR) | 62 (45-69), (59-66) | 63 (16-73), (58-67) | .69 |
| Year of transplantation, n (%) | |||
| 2012-2015 | – | 58 (95) | |
| 2016-2018 | 25(100) | 3 (5) | |
| Donor type, HLA match, n (%) | <.01 | ||
| sUCB, 4/6 | 4 (16) | 1 (2) | |
| sUCB, 5-6/6 | 11 (44) | 5 (8) | |
| dUCB | 10 (40) | 55 (90) | |
| Diagnosis, n (%) | .88 | ||
| ALL | 2 (8) | 7 (12) | |
| AML | 12 (38) | 18 (30) | |
| MDS | 2 (8) | 15 (25) | |
| CLL | 0 | 4 (7) | |
| NHL/Hodgkin lymphoma | 5 (20) | 11 (18) | |
| Multiple myeloma | 3 (12) | 1 (2) | |
| Other malignancy | 1 (4) | 5 (8) | |
| DRI, n (%) | .62 | ||
| Low | 1 (4) | 6 (10) | |
| Intermediate | 17 (68) | 39 (64) | |
| High | 7 (28) | 14 (23) | |
| Very high | 0 | 2 (3) | |
| Conditioning, n (%) | .26 | ||
| RIC: Cy/Flu/TBI | 16 (64) | 31 (51) | |
| RIC: Cy/Flu/TBI/ATG | 9 (36) | 30 (49) | |
| GVHD prophylaxis: Siro/MMF, n (%) | 25 (100) | 61 (100) | |
| KPS at admission, n (%) | <.01 | ||
| <80 | 2 (8) | 1 (2) | |
| ≥80 | 23 (92) | 60 (98) | |
| HCT-CI, n (%) | |||
| Low risk (0) | 5 (20) | 15 (25) | |
| Intermediate risk (1-2) | 10 (40) | 29 (48) | |
| High risk (3+) | 10 (40) | 17 (28) | |
| Positive CMV serostatus, n (%) | 18 (72) | 32 (52) | .10 |
| TNC dose, × 107/kg, median (range), (IQR) | 3.4 (2.4-8.4), (3.0-4.1) | 4.1 (2.2-9.6), (3.4-5.1) | .02 |
| CD34 dose, × 106/kg, median (range), (IQR) | .4 (.1-1.5), (.2-.5) | .5 (.02-2.4), (.3-.8) | .04 |
| Grade II-IV acute GVHD, %, median (95% CI) | 28 (11-45) | 36 (24-48) | .42 |
| Duration of foscarnet therapy, d, median (range), (IQR) | 16 (2-23), (10-20) | ||
| Follow-up, yr, median (range) | 3.2 (.8-3.7) | 5.5 (2.3-7.0) |
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; CR, complete remission; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index.